Updated:
MD Holdings
MD Holdings was established in 2016 by Dan Henn. The firm’s capital originates from Henn’s prior leadership at StatLab Medical Products, which he expanded...
MD Holdings
MD Holdings was established in 2016 by Dan Henn. The firm’s capital originates from Henn’s prior leadership at StatLab Medical Products, which he expanded before its majority sale. Ryan Mack and Steve Bosio joined as Partner and Operating Partner respectively. The firm executes buyouts and growth investments through direct control positions. It targets companies in healthcare services, industrial technology and digital health. Confirmed holdings include board seats at Delasco, Nuance Medical, Neurobiologix and FactoryMation. Additional investments have been made in Mission Veterinary Partners and HealthMark Group. Activity spans North America and Asia. Capital is deployed via private equity structures and select co-investments rather than fund commitments. MD Holdings maintains a small team of three named professionals. Ryan Mack served as Interim CEO of Neurobiologix in 2024 and Interim Vice President of Operations at Delasco in 2025. The firm does not disclose AUM or headcount. No philanthropic vehicles or external club memberships are listed. MD Holdings differs from typical multi-family offices by retaining operating partners who assume interim management roles inside portfolio companies. This structure ties compensation and oversight directly to execution inside acquired businesses rather than external manager selection.
General information
Firm type
Multi Family Office
Year founded
2016
Location
Region
North America
Country
United States
City
Plano
Corporate office
Richardson, TX, United States
Principals
Dan Henn
Managing Partner
Ryan Mack
Partner
Steve Bosio
Operating Partner
Sector focus
Frequently asked questions
Who runs investment decisions at MD Holdings?
Dan Henn serves as Managing Partner and leads acquisition decisions. Ryan Mack and Steve Bosio participate in board oversight and operational execution at portfolio companies.
How does MD Holdings source proprietary deal flow?
The firm relies on direct outreach and relationships built through prior operating experience in healthcare distribution and medical products.
Does MD Holdings participate in fund commitments or only direct deals?
MD Holdings executes direct control acquisitions and holds board seats. No fund commitments are disclosed.
What investment stages does MD Holdings typically target?
The firm focuses on buyouts and growth equity in lower-middle-market companies. It also lists seed and venture capital among confirmed stages.
Where does the underlying wealth come from?
Wealth originates from Dan Henn’s 2017 majority sale of StatLab Medical Products, a diagnostic supplies manufacturer he led from 2009 to 2016.
What is MD Holdings known posture on co-investments alongside external GPs?
The firm does not disclose participation in external GP-led co-investments. All documented activity occurs through direct ownership.
How is MD Holdings structured relative to its portfolio companies?
MD Holdings maintains operating partners who take interim executive roles inside holdings, including CEO and VP positions at Neurobiologix and Delasco in 2024 and 2025.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: